Figure 1

Diarrhoea incidence (yes or no) experienced by TKI treated CML patients. Patients stratified by imatinib (IM) and dasatinib (DAS) treatment and gender. Histogram represent data from Table 1. Actual patient numbers are incorporated within the histogram bars.